



# MARKETSCAN STUDIES

## Abbreviated Bibliography

Since 1988, healthcare researchers have used MarketScan® data to understand disease progression, treatment patterns, health outcomes, and their associated costs to patients, employers, health plans, and the government. Fully HIPAA compliant, the MarketScan databases from Thomson Reuters are the gold standard in proprietary databases used for healthcare research in the United States. They are the basis of over 275 peer-reviewed articles published in leading journals since the first article appeared in *The New England Journal of Medicine* in 1990 (J.B. Hillman et al.). MarketScan-based research has made a substantial contribution to the body of literature used to formulate policy decisions and improve healthcare for Americans.

### 2009

---

Azzone V, Frank RG, Pakes JR, Earle CC, Hassett MJ. Behavioral health services for women who have breast cancer. *Journal of Clinical Oncology* 2009; 27(5): 706–12.

Balkrishnan R, Pollack M, Joish VN, Asche CV, Pawaskar MD, Cziraky MJ. An economic evaluation of therapeutic alteration in the management of insomnia. *Current Medical Research and Opinion* 2009; Jan 30; [Epub ahead of print].

Carls G, Li T, Panopolis P, Wang S, Mell AG, Gibson TB, Goetzel RZ. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. *Journal of Occupational and Environmental Medicine* 2009; 51(1): 66–79.

Chu E, Schulman KL, Zelt S, Song X. Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. *Cancer* 2009; 115(7): 1412–23.

Citrome L, Reist C, Palmer L, Montejano L, Lenhart G, Cuffel B, Harnett J, Sanders KN. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. *Schizophrenia Research* 2009; 108(1–3): 238–44.

Encinosa WE, Bernard DM, Du D, Steiner CA. Recent improvements in bariatric surgery outcomes. *Medical Care* 2009; 47(5): 531–5.

Lee DW, Gibson TB, Carls GS, Ozminkowski RJ, Wang S, Stewart EA. Uterine fibroid treatment patterns in a population of insured women. *Fertility and Sterility* 2009; 91(2): 566–74.

Lee DW, Stang PE, Goldberg GA, Haberman M. Resource use and cost of diagnostic workup of women with suspected breast cancer. *The Breast Journal* 2009; 15(1): 85–92.



- Mark TL, Gibson TB, McGuigan KA. The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures. *American Journal of Managed Care* 2009; 15(2): 123–31.
- McLaurin KK, Hall CB, Jackson EA, Owens OV, Mahadevia PJ. Persistence of morbidity and cost differences between late-preterm and term infants during the first year of life. *Pediatrics* 2009; 123(2): 653–9.
- Nair KV, Tang B, Van Den Bos J, Zhang V, Saseen JJ, Naim A, Rahman M. Categorization of infliximab dose changes and healthcare utilization and expenditures for patients with rheumatoid arthritis in commercially insured and Medicare-eligible populations. *Current Medical Research and Opinion* 2009; 25(2): 303–14.
- Silverman S, Dukes EM, Johnston SS, Brandenburg NA, Sadosky A, Huse DM. The economic burden of fibromyalgia: Comparative analysis with rheumatoid arthritis. *Current Medical Research and Opinion* 2009; 25(4): 829–40.
- Wish J, Schulman K, Law A, Nassar G. Healthcare expenditure and resource utilization in patients with anaemia and chronic kidney disease: A retrospective claims database analysis. *Kidney and Blood Pressure Research* 2009; 32(2): 110–118.

## 2008

.....

- Baser O, Palmer L, Stephenson J. The estimation power of alternative comorbidity indices. *Value in Health* 2008; May 16; [Epub ahead of print].
- Boulet SL, Molinari NA, Grosse SD, Honein MA, Correa-Villaseñor A. Health care expenditures for infants and young children with Down syndrome in a privately insured population. *The Journal of Pediatrics* 2008; 153(2): 241–6.
- Carls GS, Lee DW, Ozminkowski RJ, Wang S, Gibson TB, Stewart E. What are the total costs of surgical treatment for uterine fibroids? *Journal of Women's Health* 2008; 17(7):1119–32.
- Chernew M, Gibson TB, Yu-Isenberg K, Sokol MC, Rosen AB, Fendrick AM. Effects of increased patient cost sharing on socioeconomic disparities in health care. *Journal of General Internal Medicine* 2008; 23(8): 1131–6.
- Cho BH, Kolasa MS, Messonnier ML. Influenza vaccination coverage rate among high-risk children during the 2002–2003 influenza season. *American Journal of Infection Control* 2008; 36(8): 582–7.
- Cohen LJ, Allen JC Jr. Estimating the potential savings with vagus nerve stimulation for treatment-resistant depression: A payer perspective. *Current Medical Research and Opinion* 2008; 24(8): 2203–17.
- Cohen R, Robinson D Jr, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. *Inflammatory Bowel Diseases* 2008; 14(6): 738–43.



- Curkendall SM, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois, RW. Compliance with biologic therapies for rheumatoid arthritis: Do patient out-of-pocket payments matter? *Arthritis and Rheumatism* 2008; 59(10): 1519-26
- Durden ED, Huse D, Ben-Joseph R, Chu BC. Economic costs of obesity to self-insured employers. *Journal of Occupational and Environmental Medicine* 2008; 50(9): 991-7.
- Dworkin RH, White R, O'Connor AB, Hawkins K. Health care expenditure burden of persisting herpes zoster pain. *Pain Medicine* 2008; 9(3): 348-53.
- Encinosa WE, Hellinger FJ. The impact of medical errors on ninety-day costs and outcomes: An examination of surgical patients. *Health Services Research* 2008; 43(6): 2067-85.
- Foster SA, Foley KA, Meadows ES, Johnston JA, Wang S, Pohl GM, Long SR. Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates. *BMC Women's Health* 2008; 8(1): 24.
- Foster SA, Foley KA, Meadows ES, Johnston JA, Wang S, Pohl GM, Long SR. Characteristics of patients initiating teriparatide for the treatment of osteoporosis. *Osteoporosis International* 2008; 19(3): 373-7.
- Gibson TB, Ng E, Ozminkowski RJ, Wang S, Burton WN, Goetzel RZ, Maclean R. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. *Journal of Occupational and Environmental Medicine* 2008; 50(11): 1261-1272.
- Gilman BH, Kautter J. Impact of multitiered copayments on the use and cost of prescription drugs among medicare beneficiaries. *Health Services Research* 2008; 43(2): 478-95.
- Harpaz-Rotem I, Rosenheck RA, Mohamed S, Desai RA. Pharmacologic treatment of posttraumatic stress disorder among privately insured Americans. *Psychiatric Services* 2008; 59(10): 1184-90.
- Hawkins K, Wang S, Rupnow M. Direct cost burden among insured US employees with migraine. *Headache* 2008; 48(4): 553-63.
- Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. *Current Medical Research and Opinion* 2008; 24(2): 469-80.
- Kimball AB, Robinson D Jr, Wu Y, Guzzo C, Yeilding N, Paramore C, Fraeman K, Bala M. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. *Dermatology* 2008; 217(1): 27-37.
- Kranzler HR, Stephenson JJ, Montejano L, Wang S, Gastfriend DR. Persistence with oral naltrexone for alcohol treatment: Implications for health-care utilization. *Addiction* 2008; 103(11): 1801-8.
- Kuo TC, Zhao Y, Weir S, Kramer MS, Ash AS. Implications of comorbidity on costs for patients with Alzheimer disease. *Medical Care* 2008; 46(8): 839-46.
- Loftus EV Jr, Delgado DJ, Friedman HS, Sandborn WJ. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. *The American Journal of Gastroenterology* 2008; 103(7): 1737-45.



- Logan JE, Riley AW, Barker LE. Parental mental and pain-related health and pediatric ambulatory care sensitive emergency department visits and hospitalizations. *Health Services Research* 2008; 43(2): 656–674.
- Mark TL. Receipt of psychotherapy by adolescents taking antidepressants. *Psychiatric Services* 2008; 59(9): 963.
- Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. *Journal of Managed Care Pharmacy* 2008; 14(5): 451–61.
- Ouyang L, Grosse SD, Kenneson A. Health care utilization and expenditures for children and young adults with muscular dystrophy in a privately insured population. *Journal of Child Neurology* 2008; 23(8): 883–8.
- Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. *Journal of Clinical Oncology* 2008; 26(4): 556–62.
- Peters PH, Moscona A, Schulman KL, Barr CE. Study of the impact of oseltamivir on the risk for pneumonia and other outcomes of influenza, 2000-2005. *Medscape Journal of Medicine* 2008; 10(6): 131.
- Prosser LA, O'Brien MA, Molinari NA, Hohman KH, Nichol KL, Messonnier ML, Lieu TA. Non-traditional settings for influenza vaccination of adults: Costs and cost effectiveness. *Pharmacoeconomics* 2008; 26(2): 163–78.
- Robinson D Jr, Eisenberg D, Nietert PJ, Doyle M, Bala M, Paramore C, Fraeman K, Renahan K. Systemic sclerosis prevalence and comorbidities in the US, 2001-2002. *Current Medical Research and Opinion* 2008; 24(4): 1157–66.
- Robinson JW. Regression tree boosting to adjust health care cost predictions for diagnostic mix. *Health Services Research* 2008; 43(2): 755–72.
- Romanowicz M, Stephenson JJ, Del Rosso JQ, Lenhart G. Healthcare utilization and costs of patients with rosacea in an insured population. *Journal of Drugs in Dermatology* 2008; 7(1): 41–9.
- Schneider JE, Li P, Klepser DG, Peterson NA, Brown TT, Scheffler RM. The effect of physician and health plan market concentration on prices in commercial health insurance markets. *International Journal of Health Care Finance and Economics* 2008; 8(1): 13–26.
- Shimabukuro TT, Grosse SD, Rice C. Medical expenditures for children with an autism spectrum disorder in a privately insured population. *Journal of Autism and Developmental Disorders* 2008; 38(3): 546–52.
- Sunycz JA, Mucha L, Baser O, Barr CE, Amonkar MM. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. *Osteoporosis International* 2008; 19(10): 1421–9.
- Tao G, Irwin KL. Receipt of HIV and STD testing services during routine general medical or gynecological examinations: Variations by patient sexual risk behaviors. *Sexually Transmitted Diseases* 2008; 35(2): 167–71.



- Tao G, Zhang CX. HIV testing of commercially insured patients diagnosed with sexually transmitted diseases. ***Sexually Transmitted Diseases*** 2008; 35(1):43–6.
- Taylor CA, Braza D, Rice JB, Dillingham T. The incidence of peripheral nerve injury in extremity trauma. ***American Journal of Physical Medicine and Rehabilitation*** 2008; 87(5): 381–5.
- Wang MT, Skrepnek GH, Armstrong E, Sherrill DL, Harris RB, Tsai CL, Malone DC. Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma. ***Current Medical Research and Opinion*** 2008; 24(3): 859–67.
- Wish JB, Nassar GM, Schulman K, del Aguila M, Provenzano R. Postdialysis outcomes associated with consistent anemia treatment in predialysis patients with chronic kidney disease. ***Clinical Nephrology*** 2008; 69(4): 251–9.
- Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: Analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. ***Bulletin of the NYU Hospital for Joint Diseases*** 2008; 66(2): 77–85.
- Zhao Y, Kuo TC, Weir S, Kramer MS, Ash AS. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's. ***BMC Health Services Research*** 2008; 8(1): 108.
- Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004. ***Pediatrics*** 2008; 121(2): 253–60.

## 2007

.....

- Azrin ST, Huskamp HA, Azzone V, Goldman HH, Frank RG, Burnam MA, Normand SL, Ridgely MS, Young AS, Barry CL, Busch AB, Moran G. Impact of full mental health and substance abuse parity for children in the Federal Employees Health Benefits Program. ***Pediatrics*** 2007; 119(2): e452–9.
- Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. ***Psychiatric Services*** 2007; 58(1): 85–91.
- Barr C, Schulman K, Iacuzio D, Bradley J. Effect of oseltamivir on the risk of pneumonia and use of health care services in children with clinically diagnosed influenza. ***Current Medical Research and Opinion*** 2007; 23(3): 523–31.
- Baser O. Using propensity score matching techniques for average treatment effect: Application to triptan use. In ***Proceedings of the International Conference on Health Policy Research***, October 28–30 2005, Boston, MA. American Statistical Association; 2007: 4334–4339.
- Baser O. Modeling transformed health care cost with unknown heteroskedasticity. ***Applied Economic Research*** 2007; 01: 1–6.



- Blumentals WA, Schulman KL. Impact of oseltamivir on the incidence of secondary complications of influenza in adolescent and adult patients: Results from a retrospective population-based study. **Current Medical Research and Opinion** 2007; 23(12):2961–70.
- Blumentals WA, Song X. The safety of oseltamivir in patients with influenza: Analysis of healthcare claims data from six influenza seasons. **Medscape General Medicine** 2007; 9(4): 27–32.
- Botteman MF, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: A decision analytical model. **CNS Drugs** 2007; 21(4): 319–334.
- Brixner DI, Lenhart G, Young DC, Samuelson WM. The effect of fixed combination of fluticasone and salmeterol on asthma drug utilization, asthma drug cost, and episodes of asthma exacerbations. **Current Medical Research and Opinion** 2007; 23(11): 2887–95.
- Dworkin RH, White R, O'Connor AB, Baser O, Hawkins K. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. **Journal of the American Geriatrics Society** 2007; 55(8): 1168–75.
- Fitch K, Pyenson B, Iwasaki K. Metabolic syndrome and employer sponsored medical benefits: An actuarial analysis. **Value in Health** 2007; 10(Suppl 1): S21–8.
- Foley KA, Foster SA, Meadows ES, Baser O, Long SR. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. **Medical Care** 2007; 45(9): 902–6.
- Gilman BH, Kautter J. Consumer response to dual incentives under multitiered prescription drug formularies. **The American Journal of Managed Care** 2007; 13(6 Pt 2): 353–9.
- Hawkins K, Wang S, Rupnow MF. Indirect cost burden of migraine in the United States. **Journal of Occupational and Environmental Medicine** 2007; 49(4): 368–374.
- Kahende JW, Woollery TA, Lee CW. Assessing medical expenditures on 4 smoking-related diseases, 1996–2001. **American Journal of Health Behavior** 2007; 31(6): 602–611.
- Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS. Health care cost associated with prostate cancer, androgen deprivation therapy, and bone complications. **The Journal of Urology** 2007; 178(4 Pt 1): 1423–8.
- Kutikova L, Bowman L, Chang S, Long SR, Thornton DE, Crown WH. Utilization and cost of health care services associated with primary malignant brain tumors in the United States. **Journal of Neurooncology** 2007; 81(1): 61–5.
- Larson MJ, Miller K, Fleming KJ. Treatment with antidepressant medications in private health plans. **Administration and Policy in Mental Health and Mental Health Services Research** 2007; 34(2): 116–26.
- Larson MJ, Miller K, Fleming KJ, Teich JL. Mental health services for children in large, employer-based health plans, 1999. **The Journal of Behavioral Health Services and Research** 2007; 34(1): 56–72.



- Lee DW, Ozminkowski RJ, Carls GS, Wang S, Gibson TB, Stewart EA. The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids. *Journal of Occupational and Environmental Medicine* 2007; 49(5): 493–506.
- Mackenzie EJ, Castillo RC, Jones AS, Bosse MJ, Kellam JF, Pollak AN, Webb LX, Swiontkowski MF, Smith DG, Sanders RW, Jones AL, Starr AJ, McAndrew MP, Patterson BM, Burgess AR. Health care costs associated with amputation or reconstruction of a limb-threatening injury. *The Journal of Bone and Joint Surgery* 2007; 89(8): 1685–92.
- Mark T, Axelsen K, Mucha L, Sadkova Y. Racial differences in switching, augmentation and titration of lipid-lowering agents by Medicare/Medicaid dual-eligible patients. *The American Journal of Managed Care* 2007; 13 Suppl 3: S72–9.
- Mirkin D, Murphy-Barron C, Iwasaki K. Actuarial analysis of private payer administrative claims data for women with endometriosis. *Journal of Managed Care Pharmacy* 2007; 13(3): 262–72.
- Molinari N, Kolasa M, Messonnier M, Schieber R. Out-of-pocket costs of childhood immunizations: A comparison by type of insurance plan. *Pediatrics* 2007; 120(5): e1148–56.
- Molinari N, Ortega-Sanchez I, Messonnier M, Thompson W, Wortley P, Weintraub E, Bridges C. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. *Vaccine* 2007; 25(27): 5086–5096.
- Mortimer JE, Schulman K, Kohles JD. Patterns of bisphosphonate use in the United States in the treatment of metastatic bone disease. *Clinical Breast Cancer* 2007; 7(9): 682–9.
- Ohsfeldt RL, Lage MJ, Rajagopalan K. Medication use, service utilization, and medical costs associated with new episodes of bipolar disorder: Evidence from a retrospective claims database. *Primary Care Companion to the Journal of Clinical Psychiatry* 2007; 9(4): 280–6.
- Orzeck EA, Shi N, Blumentals WA. Oseltamivir and the risk of influenza-related complications and hospitalizations in patients with diabetes. *Clinical Therapeutics* 2007; 29(10): 2246–55.
- Ouyang L, Grosse SD, Armour BS, Waitzman NJ. Health care expenditures of children and adults with spina bifida in a privately insured U.S. population. *Birth Defects Research. Part A, Clinical and Molecular Teratology* 2007; 79(7): 552–8.
- Ozminkowski RJ, Wang S, Long SR. The impact of nebulized levalbuterol on health care payments for elderly asthma and chronic obstructive pulmonary disease patients in Medicaid plans. *Disease Management and Health Outcomes* 2007; 15(1): 41–55.
- Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in the United States. *Sleep* 2007; 30(3): 263–73.
- Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. *Journal of Managed Care Pharmacy* 2007; 13(1): 44–52.
- Rousculp MD, Long SR, Wang S, Schoenfeld MJ, Meadows ES. Economic burden of osteoporosis-related fractures in Medicaid. *Value in Health* 2007; 10(2): 144–52.



- Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. **Cancer** 2007; 109(11): 2334–42.
- Shih YC, Bekele NB, Xu Y. Use of bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients. **Pharmacoeconomics** 2007; 25(10): 843–62.
- Suh DC, Kahler KH, Choi IS, Shin H, Kralstein J, Shetzline M. Patients with irritable bowel syndrome or constipation have an increased risk for ischaemic colitis. **Alimentary Pharmacology & Therapeutics** 2007; 25(6): 681–92.
- Suh DC, Sung J, Gause D, Raut M, Huang J, Choi IS. Economic burden of atopic manifestations in patients with atopic dermatitis—Analysis of administrative claims. **Journal of Managed Care Pharmacy** 2007; 13(9): 778–89.
- Wynn ML, Chang S, Peipins LA. Temporal patterns of conditions and symptoms potentially associated with ovarian cancer. **Journal of Women's Health** 2007; 16(7): 971–86.
- Ye X, Gross CR, Schommer J, Cline R, Xuan J, St. Peter WL. Initiation of statins after hospitalization for coronary heart disease. **Journal of Managed Care Pharmacy** 2007; 13(5): 385–96.
- Yoon EY, Dombkowski KJ, Rocchini A, Lin JJ, Davis MM. Off-label utilization of antihypertensive medications in children. **Ambulatory Pediatrics** 2007; 7(4): 299–303.
- Zhan C, Elixhauser A, Friedman B, Houchens R, Chiang YP. Modifying DRG-PPS to include only diagnoses present on admission: Financial implications and challenges. **Medical Care** 2007; 45(4): 288–91.
- Zhang P, Imai K. The relationship between age and healthcare expenditure among persons with diabetes mellitus. **Expert Opinion on Pharmacotherapy** 2007; 8(1): 49–57.
- Zhou F, Kyaw MH, Shefer A, Winston CA, Nuorti JP. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. **Archives of Pediatrics & Adolescent Medicine** 2007; 161(12): 1162–8.
- Zhou F, Shefer A, Weinbaum C, McCauley M, Kong Y. Impact of hepatitis A vaccination on health care utilization in the United States, 1996–2004. **Vaccine** 2007; 25(18): 3581–7.
- Zuckerman IH, Sato M, Hsu VD, Hernandez JJ. Validation of a method for identifying nursing home admissions using administrative claims. **BMC Health Services Research** 2007; 7(1): 202.

## 2006

---

- Baser O. Too much ado about propensity score models? Comparing methods of propensity score matching. **Value in Health** 2006; 9(6): 377–85.
- Baser O, Crown WH, Pollicino C. Guidelines for selecting among different types of bootstraps. **Current Medical Research and Opinion** 2006; 22(4): 799–808.





- Briesacher BA, Orwig D, Seton M, Omar M, Kahler KH. Medical care costs of Paget's disease of bone in a privately insured population. *Bone* 2006; 38(5): 731–7.
- Campbell K, Lanza A, Dixon R, Chattopadhyay S, Molinari N, Finch R, editors. *A Purchaser's Guide to Clinical Preventive Services: Moving Science into Coverage*. Washington, DC: National Business Group on Health; 2006.
- Chang S, Long SR, Kutikova L, Bowman L, Crown WH, Lyman GH. Burden of pancreatic cancer and disease progression: Economic analysis in the US. *Oncology* 2006; 70(1): 71–80.
- Erbán JK, Lau J. On the toxicity of chemotherapy for breast cancer—The need for vigilance. *Journal of the National Cancer Institute* 2006; 98(16): 1096–1097.
- Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. *American Journal of Managed Care* 2006; 12(12 Spec No): SP11–9.
- Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. *American Journal of Managed Care* 2006; 12(9): 509–17.
- Goldman HH, Frank RG, Burnam MA, Huskamp HA, Ridgely MS, Normand ST, Young AS, Barry CL, Azzone V, Busch AB, Azrin ST, Moran G, Lichtenstein C, Blasinsky M. Behavioral health insurance parity for federal employees. *The New England Journal of Medicine* 2006; 354(13): 1378–1386.
- Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. *Journal of the National Cancer Institute* 2006; 98(16): 1108–17.
- Huse DM, Castelli-Haley J, Orsini LS, Lenhart G, Abdalla JA. Patterns of initial pharmacotherapy for Parkinson's disease in the United States. *Journal of Geriatric Psychiatry and Neurology* 2006; 19(2): 91–97.
- Huse DM, Song X, Ozminkowski RJ, Maguire J, Williams SA, Borok GM, McDonough K. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis. *Clinical Therapeutics* 2006; 28(9): 1425–42.
- Kutikova L, Bowman L, Chang S, Long SR, Arning M, Crown WH. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. *Leukemia & Lymphoma* 2006; 47(8): 1535–44.
- Lage MJ, Castelli-Haley J, Oleen-Burkey MA. Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis. *Work* 2006; 27(2): 143–51.
- Mucha L, Masia NA, Axelsen KJ. Per-patient-per-month drug costs in Medicare Part D protected classes. *Pharmacoeconomics* 2006; 24 Suppl 3: 79–84.
- Ohsfeldt RL, Borisov NM, Sheer RL. Fragility fracture-related direct medical costs in the first year following a nonvertebral fracture in a managed care setting. *Osteoporosis International* 2006; 17(2): 252–258.



- Ozminkowski RJ, Burton WN, Goetzel RZ, Maclean R, Wang S. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. ***Journal of Occupational and Environmental Medicine*** 2006; 48(2): 135–148.
- Ozminkowski RJ, Goetzel RZ, Shechter D, Stapleton DC, Baser O, Lapin P. Predictors of preventive service use among Medicare beneficiaries. ***Health Care Financing Review*** 2006; 27(3): 5–23.
- Prosser L, Bridges C, Uyeki T, Hinrichsen V, Meltzer M, Molinari N, Schwartz B, Thompson W, Fukuda K, Lieu T. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. ***Emerging Infectious Diseases*** 2006; 12(10): 1548–1558.
- Robinson RL, Long SR, Chang S, Able S, Baser O, Obenchain RL, Swindle RW. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: Analysis of administrative claims. ***Journal of Managed Care Pharmacy*** 2006; 12(1): 43–54.
- Song X, Huse DM, Williams SA, Borok GM, McDonough K, Ozminkowski RJ. A projection of the impact of lipid-lowering therapy on high-risk employee disability and medical costs. ***Journal of Occupational and Environmental Medicine*** 2006; 48(10): 1014–22.
- Stallings SC, Huse D, Finkelstein SN, Crown WH, Witt WP, Maguire J, Hiller AJ, Sinsky AJ, Ginsburg GS. A framework to evaluate the economic impact of pharmacogenomics. ***Pharmacogenomics*** 2006; 7(6): 853–62.
- Tchernis R, Normand ST, Pakes J, Gaccione P, Newhouse JP. Selection and plan switching behavior. ***Inquiry*** 2006; 43: 10–22.

## 2005

.....

- Beinart SC, Kolm P, Veledar E, Zhang Z, Mahoney EM, Bouin O, Gabriel S, Jackson J, Chen R, Caro J, Steinhubl S, Topol E, Weintraub WS. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: Results from the clopidogrel for the reduction of events during observation (CREDO) trial. ***Journal of the American College of Cardiology*** 2005; 46(5): 761–769.
- Berndt E, Crown W, Kallich J, Long S, Song X, Lyman GH. The impact of anaemia and its treatment on employee disability and medical costs. ***Pharmacoeconomics*** 2005; 23(2): 183–192.
- Chang J, Sung J. Health plan budget impact analysis for pimecrolimus. ***Journal of Managed Care Pharmacy*** 2005; 11(1): 66–77.
- Chattopadhyay SK, Ebrahim SH, Tao G, McKenna MT. Use of cervical cancer screening among insured women: The extent of missed opportunities. ***Health Policy*** 2005; 73(2): 194–201.
- Dillingham TR, Pezzin LE. Under-recognition of polyneuropathy in persons with diabetes by nonphysician electrodiagnostic services providers. ***American Journal of Physical Medicine and Rehabilitation*** 2005; 84(6): 399–406.



- Encinosa WE, Bernard DM, Steiner CA, Chen CC. Use and costs of bariatric surgery and prescription weight-loss medications. *Health Affairs* 2005; 24(4): 1039–1046.
- Finkel S, Kozma C, Long S, Greenspan A, Mahmoud R, Baser O, Engelhart L. Risperidone treatment in elderly patients with dementia: Relative risk of cerebrovascular events versus other antipsychotics. *International Psychogeriatrics* 2005; 17(4): 1–13.
- Gibson TB, McLaughlin CG, Smith DG. A copayment increase for prescription drugs: The long-term and short-term effects on use and expenditures. *Inquiry* 2005; 42: 293–310.
- Hansen RA, Schommer JC, Cline RR, Hadsall RS, Schondelmeyer SW, Nyman JA. The association of consumer cost-sharing and direct-to-consumer advertising with prescription drug use. *Research in Social & Administrative Pharmacy* 2005; 1(2): 139–57.
- Hansen RA, Shaheen NJ, Schommer JC. Factors influencing the shift of patients from one proton pump inhibitor to another: The effect of direct-to-consumer advertising. *Clinical Therapeutics* 2005; 27(9): 1478–1487.
- Harpaz-Rotem I, Leslie DL, Martin A, Rosenheck RA. Changes in child and adolescent inpatient psychiatric admission diagnoses between 1995 and 2000. *Social Psychiatry and Psychiatric Epidemiology* 2005; 40(8): 642–647.
- Hellinger FJ, Encinosa WE. Inappropriate drug combinations among privately insured patients with HIV disease. *Medical Care* 2005; 43(9 Suppl.): III53–62.
- Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. *Movement Disorders* 2005; 20(11): 1449–1454.
- Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. *Journal of General Internal Medicine* 2005; 20(8): 748–753.
- Kinchen KS, Long S, Chang S, Girts TK, Pantos B. The direct cost of stress urinary incontinence among women in a Medicaid population. *American Journal of Obstetrics & Gynecology* 2005; 193(6): 1936–1944.
- Kniesner TJ, Powers RH, Croghan TW. Provider type and depression treatment adequacy. *Health Policy* 2005; 72(3): 321–332.
- Kuehn BM. Better osteoporosis management a priority: Impact predicted to soar with aging population. *Journal of the American Medical Association* 2005; 293: 2453–2458.
- Kutikovaa L, Bowman L, Chang S, Long SR, Obasajua C, Crown WH. The economic burden of lung cancer and the associated costs of treatment failure in the United States. *Lung Cancer* 2005; 50(2): 143–154.
- Litwin MS, Saigal CS, Yano EM, Avila C, Geschwind SA, Hanley JM, Joyce GF, Madison R, Pace J, Polich SM, Wang M. Urologic diseases in America project: Analytical methods and principal findings. *Journal of Urology* 2005; 173(3): 933–937.
- Lyman GH, Berndt ER, Kallich JD, Erder MH, Crown WH, Long SR, Lee H, Song X, Finkelstein SN. The economic burden of anemia in cancer patients receiving chemotherapy. *Value in Health* 2005; 8(2): 149–156.



- Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. **American Journal of Managed Care** 2005; 11(5 Suppl.): S170–176.
- Marciniak MD, Lage MJ, Dunayevich E, Russell JM, Bowman L, Landbloom RP, Levine LR. The cost of treating anxiety: The medical and demographic correlates that impact total medical costs. **Depression and Anxiety** 2005; 21(4): 178–84.
- Mark TL, Ozminkowski RJ. What will be the impact of the Medicare doughnut hole? **Drug Benefit Trends** 2005; June: 254–260.
- Nissenson AR, Wade S, Goodnough T, Knight K, Dubois RW. Economic burden of anemia in an insured population. **Journal of Managed Care Pharmacy** 2005; 11(7): 565–574.
- Rhoads GG, Orsini LS, Crown W, Wang S, Getahun D, Zhang Q. Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. **Journal of Occupational and Environmental Medicine** 2005; 47(5): 447–452.
- Roy K, Wang SA, Meltzer MI. Optimizing treatment of antimicrobial-resistant neisseria gonorrhoeae. **Emerging Infectious Disease** 2005; 11(8): 1265–1273.
- Russo PA, Smith MW, Namjoshi M. Health care costs for schizophrenia patients started on olanzapine versus risperidone. **American Journal of Health-System Pharmacy** 2005; 62(6): 610–615.
- Slade EP, Salkever DS, Rosenheck R, Swanson J, Swartz M, Shern D, Gallucci G, Harding C, Palmer L, Russo P, Hough RL, Barrio C, Garcia P. Cost-sharing requirements and access to mental health care among Medicare enrollees with schizophrenia. **Psychiatric Services** 2005; 56(8): 960–6.
- Splete H. Compliance issues seen with bisphosphonate regimens. **OB/GYN News** 2005; May 15.
- Suh D, Thomas SK, Valiyeva E, Arcona S, Vo L. Drug persistency of two cholinesterase inhibitors: Rivastigmine versus donepezil in elderly patients with Alzheimer's disease. **Drugs & Aging** 2005; 22(8): 695–707.
- Tao G, Patterson E, Lee LM, Sansom S, Teran S, Irwin KL. Estimating prenatal syphilis and HIV screening rates for commercially insured women. **American Journal of Preventative Medicine** 2005; 28(2): 175–81.
- Zhao Y, Ash AS, Ellis RP, Ayanian JZ, Pope GC, Bowen B, Weyuker L. Predicting pharmacy costs and other medical costs using diagnoses and drug claims. **Medical Care** 2005; 43(1): 34–43.
- Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. **Journal of the American Medical Association** 2005; 294(7): 797–802.

## 2004

.....

- Berg GD, Chattopadhyay SK. Determinants of hospital length of stay for cervical dysplasia and cervical cancer: Does managed care matter? **American Journal of Managed Care** 2004; 10(1): 33–38.



- Briesacher B, Kamal-Bahl S, Hochberg M, Orwig D, Kahler KH. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs. *Archives of Internal Medicine* 2004; 164(15): 1679–1684.
- Busch SH, Leslie DL, Rosenheck RA. Comparing the quality of antidepressant pharmacotherapy in the Department of Veterans Affairs and the private sector. *Psychiatric Services* 2004; 55(12): 1386–1391.
- Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, Bennett CL. Estimating the cost of cancer: Results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. *Journal of Clinical Oncology* 2004; 22(17): 3524–3530.
- Crown WH, Bresnahan BW, Orsini LS, Kennedy S, Leonardi C. The burden of illness associated with psoriasis: Cost of treatment with systemic therapy and phototherapy in the US. *Current Medical Research and Opinion* 2004; 20(12): 1929–1936.
- Crown WH, Berndt ER, Baser O, Finkelstein SN, Witt WP, Maguire J, Haver KE. Benefit plan design and prescription drug utilization among asthmatics: Do patient copayments matter? *Frontiers in Health Policy Research* 2004; 7: 95–127.
- Dillingham TR, Pezzin LE, Rice JB. Electrodiagnostic services in the United States. *Muscle Nerve* 2004; 29(2): 198–204.
- Donohue JM, Berndt ER, Rosenthal M, Epstein AM, Frank RG. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. *Medical Care* 2004; 42(12): 1176–85.
- Dor A, Grossman M, Koroukian SM. Hospital transaction prices and managed-care discounting for selected medical technologies. *American Economic Review* 2004; 94(2): 352–356.
- Dor A, Koroukian SM, Grossman M. Managed care discounting: Evidence from the MarketScan database. *Inquiry* 2004; Summer: 23–33.
- Figueroa R, Harman J, Engberg J. Use of claims data to examine the impact of length of inpatient psychiatric stay on readmission rate. *Psychiatric Services* 2004; 55(5): 560–565.
- Finkelstein E, Bray J, Larson MJ, Miller K, Tompkins C, Keme A, Manderscheid R. Prevalence of, and payments for, mental health and substance abuse disorders in public and private health plans. SAMHSA/CMHS (Center for Mental Health Services) Mental Health, United States 2002, 165–185, 2004.
- Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. *Journal of Occupational and Environmental Medicine* 2004; 46(4): 398–412.
- Hansen LG. Is the glass half full or half empty? Patient dynamics underlying marketshare. *Product Management Today* 2004; 15(10): 37–39.
- Harpaz-Rotem I, Rosenheck RA. Changes in outpatient psychiatric diagnosis in privately insured children and adolescents from 1995 to 2000. *Child Psychiatry and Human Development* 2004; 34(4): 329–340.



- Hellinger FJ, Encinosa WE. Antiretroviral therapy and health care utilization: A study of privately insured men and women with HIV disease. *Health Services Research* 2004; 39(4 Pt 1): 949–967.
- Kamal-Bahl S, Briesacher B. How do incentive-based formularies influence drug selection and spending for hypertension? *Health Affairs* 2004; 23(1): 227–236.
- Kinchen, KS, Orsini L, Crown W, Bump R. Healthcare utilization among women who undergo surgery for stress urinary incontinence. *International Urogynecology Journal of Pelvic Floor Dysfunction* 2004; 15(3): 154–159.
- Mark TL. Are medications for alcoholism underutilized? An analysis of private sector and Medicaid claims. *Drug Benefit Trends* 2004; 16(3): 154–158.
- Mark TL, Coffey RM. The decline in receipt of substance abuse treatment by the privately insured, 1992–2001. *Health Affairs* 2004; 23(6): 157–162.
- Orsini L, Rousculp MD, Long SR, Wang S. Health care utilization and expenditures in the United States: A study of osteoporosis-related fractures. *Osteoporosis International* 2005; 16: 359–371. Published online: September 1, 2004.
- Orsini L, Limpa-Amara S, Crown WH, Stanford RH, Kamal K. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast. *Annals of Allergy, Asthma and Immunology* 2004; 92(5): 523–529.
- Ozminkowski RJ, Marder WD, Hawkins K, Wang S, Stallings SC, Finkelstein SN, Sinskey AJ, Wierz D. The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans. *Clinical Therapeutics* 2004; 26(8): 1341–1354.
- Pauly MV, Zeng Y. Adverse selection and the challenges to stand-alone prescription drug insurance. *Frontiers in Health Policy Research* 2004; 7: 55–74.
- Russell J, Hawkins K, Ozminkowski R, Orsini L, Crown W, Kennedy S, Finkelstein S, Berndt E, Rush J. Cost consequences of treatment-resistant depression. *Journal of Clinical Psychiatry* 2004; 65(3): 341–347.
- Stang PE, Crown WH, Bizier R, Chatterton ML, White R. The family impact and costs of migraine. *The American Journal of Managed Care* 2004; 10(5): 313–320.
- Suh DC, Arcona S, Thomas SK, Powers C, Rabinowicz AL, Shin H, Mirski D. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine. *Drugs & Aging* 2004; 21(6): 395–403.

## 2003

---

- Adams EK, Nishimura B, Merritt RK, Melvin C. Costs of poor birth outcomes among privately insured. *Journal of Health Care Finance* 2003; 29(3): 11–27.
- Atherly A, Williams SG, Redd SC. What is the cost of asthma to employers? *Drug Benefit Trends* 2003; 15(11): 35–46.



- Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for U.S. privately insured patients with type 2 diabetes. *Diabetes Care* 2003; 26(6): 1847–1851.
- Crown WH, Olufade A, Smith MW, Nathan R. Seasonal versus perennial allergic rhinitis: Drug and medical resource utilization patterns. *Value in Health* 2003; 6(4): 448–456.
- Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity cost burden of the ‘top 10’ physical and mental health conditions affecting six large U.S. employers in 1999. *Journal of Occupational and Environmental Medicine* 2003; 45(1): 5–14.
- Kinchen KS, Long S, Orsini L, Crown W, Swindle R. A retrospective claims analysis of the direct costs of stress urinary incontinence. *International Urogynecology Journal of Pelvic Floor Dysfunction* 2003; 14(6): 403–411.
- Leslie DL, Rosenheck RA. Benchmarking the quality of schizophrenia pharmacotherapy: A comparison of the department of veterans affairs and the private sector. *The Journal of Mental Health Policy and Economics* 2003; 6(3): 113–121.
- Mark TL. The costs of treating persons with depression and alcoholism compared with depression alone. *Psychiatric Services* 2003; 54(8): 1095–1097.
- Mark TL, Coffey RM. What drove private health insurance spending on mental health and substance abuse care, 1992–1999? *Health Affairs* 2003; 22(1): 165–172.
- Mark TL, Dilonardo JD, Chalk M, Coffey R. Factors associated with the receipt of treatment following detoxification. *Journal of Substance Abuse Treatment* 2003; 24(4): 299–304.
- Mark TL, Ozminkowski RJ, Kirk A, Ettner SL, Drabek J. Risk adjustment for people with chronic conditions in private sector health plans. *Medical Decision Making* 2003; 23(5): 397–405.
- Zhao Y, Ash AS, Haughton J, McMillan B. Identifying future high-cost cases through predictive modeling. *Disease Management & Health Outcomes* 2003; 11(6): 389–397.

## 2002

.....

- Berndt E, Crown W. Labor force activity in cancer patients with anemia. *Quality of Life in Oncology* 2002; 5(4): 10–13.
- Berndt ER, Bir A, Busch SH, Frank RG, Normand SL. The medical treatment of depression, 1991–1996: Productive inefficiency, expected outcome variations, and price indexes. *Journal of Health Economics* 2002; 21(3): 373–396.
- Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, Russell JM. The impact of treatment-resistant depression on health care utilization and costs. *Journal of Clinical Psychiatry* 2002; 63(11): 963–971.
- Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: The risk of asthma related hospitalizations and emergency room visits. *The Journal of Allergy and Clinical Immunology* 2002; 109(1): 57–62.



- Crystal-Peters J, Neslusan CA, Smith MW, Togias A. Health care costs of allergic rhinitis-associated conditions vary with allergy season. *Annals of Allergy, Asthma & Immunology* 2002; 89(5): 457–462.
- Crystal-Peters J, Chang S, Long S, Tretiak R. Health care expenditures of patients with major depressive disorder and post traumatic stress disorder. *European Psychiatry* 2002; 17 (1 Suppl.): 150.
- Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. *Journal of the American Academy of Dermatology* 2002; 46(6): 850–860.
- Poret AW, Ozminkowski RJ, Goetzel R, Pew JE, Balent J. Cost burden of illness for hepatitis C patients with employer-sponsored health insurance. *Disease Management* 2002; 5(2): 95–107.
- Russo P, Smith MW, Dirani R, Namjoshi M, Tohen M. Pharmacotherapy patterns in the treatment of bipolar disorder. *Bipolar Disorder* 2002; 4(6): 366–377.
- Tao G, Walsh CM, Anderson LA, Irwin KL. Understanding sexual activity defined in the HEDIS measure of screening women for chlamydia trachomatis. *The Joint Commission Journal on Quality Improvement* 2002; 28(8): 435–440.
- Wan GJ, Crown WH, Berndt ER, Finkelstein SN, Ling D. Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety. *International Journal of Clinical Practice* 2002; 56(6): 434–439.
- Wang JT, Barr CE, Torigoe Y, et al. Cost savings in migraine associated with less chest pain on new triptan therapy. *American Journal of Managed Care* 2002; 8(3 Suppl.): S102–107.
- Zhao SZ, Dodge WE, Spalding W, Barr CE, Li JZ. Length of hospital stay and cost of staphylococcus and streptococcus infections among hospitalized patients. *Clinical Therapeutics* 2002; 24(5): 818–834.

## 2001

.....

- Ash AS, Zhao Y, Ellis RP, Schlein Kramer M. Finding future high-cost cases: Comparing prior cost versus diagnosis-based methods. *Health Services Research* 2001; 36(6 Pt 2): 194–206.
- Chrischilles E, Rubenstein L, Chao J, Kreder KJ, Gilden D, Shah H. Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: A retrospective cohort study. *Clinical Therapeutics* 2001; 23(5): 727–743.
- Crown W, Wan G, Berndt E, Finkelstein S, Ling D. Differences in health care expenditures among patients treated for depression with or without anxiety. *Value in Health* 2001; 4(2): 148.
- Crown W, Treglia M, Meneades L, White A. Long-term costs of treatment for depression: Impact of drug selection and guideline compliance. *Value in Health* 2001; 4(4): 295–307.





- Crown WH, Neslusan C, Russo PA, Holzer S, Ozminkowski R, Croghan T. Hospitalization and total medical costs for privately insured persons with schizophrenia. **Administration and Policy in Mental Health** 2001; 28(5): 335–351.
- Gandhi SK, Arguelles L, Boyer JG. Economic impact of neutropenia and febrile neutropenia in breast cancer: Estimates from two national databases. **Pharmacotherapy** 2001; 21(6): 684–690.
- Gandhi SK, Reynolds MW, Boyer JG, et al. Recurrence and malignancy rates in a benign colorectal neoplasm patient cohort: Results of a 5-year analysis in a managed care environment. **American Journal of Gastroenterology** 2001; 96(9): 2761–2767.
- Leslie DL, Rosenheck RA, Horwitz SM. Patterns of mental health utilization and costs among children in a privately insured population. **Health Services Research** 2001; 36(1 Pt 1): 113–127.
- Mark TL, Woody GE, Juday T, Kleber H. The economic costs of heroin addiction in the United States. **Drug and Alcohol Dependence** 2001; 61(2): 195–206.
- McGuigan K, Sokol M, Yao J, Haynes J, Qian Q, Boscarino J, Epstein R. The value of compliance: Evidence from two patient cohorts. **Value in Health** 2001; 4(2): 55.
- Miller TR, Lestina DC, Smith GS. Injury risk among medically identified alcohol and drug abusers. **Alcoholism: Clinical and Experimental Research** 2001; 25(1): 54–59.
- Poret AW, Neslusan C, Ricci JF, Wang S, Khan ZM, Kwong JW. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants. **Value in Health** 2001; 4(5): 362–369.
- Zhao Y, Ellis RP, Ash AS, Calabrese D, Ayanian JZ, Slaughter JP, Weyuker L, Bowen B. Measuring population health risks using inpatient diagnoses and outpatient pharmacy data. **Health Services Research** 2001; 36(6) Part II: 180–193.

## 2000

.....

- Anderson DR, Whitmer RW, Goetzel RZ, Ozminkowski RJ, Dunn RL, Wasserman J, Serxner S; Health Enhancement Research Organization (HERO) Research Committee. The relationship between modifiable health risks and group-level health care expenditures. **American Journal of Health Promotion** 2000; 15(1): 45–52.
- Berndt ER, Russell JM, Miceli R, Colucci SV, Yikang X, Grudzinski AN. Comparing SSRI treatment costs for depression using retrospective claims data: The role of nonrandom selection and skewed data. **Value in Health** 2000; 3(3): 208.
- Crystal-Peters J, Crown WH, Goetzel RZ, Schutt DC. The cost of productivity losses associated with allergic rhinitis. **The American Journal of Managed Care** 2000; 6(3): 373–378.
- Dilonardo J, Chalk M, Mark TL, Coffey RM; CSAT/CMHS Spending Estimates Team. Recent trends in the financing of substance abuse treatment: implications for the future. **Health Services Research** 2000; 35(5 Pt 3): 60–71.



- Dubois RW, Chawla AJ, Neslusan CA, Smith MW, Wade S. Explaining drug spending trends: Does perception match reality? *Health Affairs* 2000; 19(2): 231–239.
- Goetzel RZ, Ozminkowski RJ, Del Rosso G, Schutt DC. Are drugs a cost or an investment? *Business & Health* 2000; June: 39–45.
- Goetzel RZ, Ozminkowski RJ, Meneades L, Stewart M, Schutt DC. Pharmaceuticals—Cost or investment? An employer’s perspective. *Journal of Occupational and Environmental Medicine* 2000; 42(4): 338–351.
- Leslie DL, Rosenheck RA. Comparing quality of mental health care for public-sector and privately insured populations. *Psychiatric Services* 2000; 51(5): 650–655.
- Mark TL, Coffey RM, King E, Harwood H, McKusick D, Genuarid J, Dilonardo J, Buck J. Spending on mental health and substance abuse treatment, 1987–1997. *Health Affairs* 2000; 19(4): 108–120.
- Mody SH, Hsu AY, Dodd SL, Mossey J, Gallagher RM. The impact of depression on health resource utilization for chronic nonmalignant pain patients. *Pain Medicine* 2000; 1(2): 204.
- Ozminkowski R, Wang S, Marder WD, Azzolini J. Short-run associations between medical care expenditures and adherence to clinical practice guideline-based measures for diabetes. *Value in Health* 2000; 3(s1): 29–38.
- Ozminkowski R, Wang S, Marder WD, Azzolini J, Schutt D. Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma. *Pharmacoeconomics* 2000; 18(3): 253–264.
- Parashar UD, Holman RC, Cummings KC, et al. Trends in intussusception-associated hospitalizations and deaths among US infants. *Pediatrics* 2000; 106(6): 1413–1421.
- Siddique R, Neslusan CA, Crown WH, Crystal-Peters J, Sloan S, Farup C. A national inpatient cost estimate of percutaneous endoscopic gastrostomy (PEG)-associated aspiration pneumonia. *The American Journal of Managed Care* 2000; 6(4): 490–496.
- Striegel-Moore RH, Leslie D, Petrill SA, Garvin V, Rosenheck RA. One-year use and cost of inpatient and outpatient services among female and male patients with an eating disorder: Evidence from a national database of health insurance claims. *International Journal of Eating Disorders* 2000; 27(4): 381–389.
- Tao G, Kassler WJ, Rein DB. Medical care expenditures for genital herpes in the United States. *Sexually Transmitted Diseases* 2000; 27(1): 32–8.
- Tao G, Walsh CM, Anderson LA, Irwin KL. Avenues to combat the silent epidemic of chlamydia infection in managed care organizations: An analysis of the HEDIS measure on screening for chlamydia trachomatis. *Preventive Medicine in Managed Care* 2000; 1: 177–183.



## 1999

---

- Brooks J, Doucette W, Sorofman B. Factors affecting bargaining outcomes between pharmacies and insurers. *Health Services Research* 1999; 34(1) Pt 2: 439–451.
- Claxton AJ, Chawla AJ, Kennedy S. Absenteeism among employees treated for depression. *Journal of Occupational and Environmental Medicine* 1999; 41(7): 605–611.
- Croghan T, Melfi C, Dobrez D, Kniesner T. Effect of mental health specialty care on antidepressant length of therapy. *Medical Care* 1999; 37(4) Lilly Suppl: AS20–3.
- Cuffel B, Wamboldt M, Borish L, Kennedy S, Crystal-Peters J. Economic consequences of comorbid depression, anxiety, and allergic rhinitis. *Psychosomatics* 1999; 40(6): 491–496.
- Goodman AC, Hankin JR, Nishiura E, Sloan JJ. Impacts of insurance on the demand and utilization of drug abuse treatment: Implications for insurance mandates. *International Journal of the Economics of Business* 1999; 6(3): 331–348.
- Herman WH, Alexander CM, Cook JR, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyorala K. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian simvastatin survival study. *Diabetes Care* 1999; 22(11): 1771–1778.
- Hu X, Markson L, Lipton R, Stewart W, Berger M. Burden of migraine in the United States: Disability and economic costs. *Archives of Internal Medicine* 1999; 159(8): 813–818.
- Hylan T, Crown W, Meneades L, Heiligenstein J, Melfi C, Croghan T, Buesching D. SSRI antidepressant drug use patterns in the naturalistic setting: A multivariate analysis. *Medical Care* 1999; 37(4) Lilly Suppl: AS36–44.
- Leslie DL, Rosenheck R. Changes in inpatient mental health utilization and costs in a privately insured population, 1993 to 1995. *Medical Care* 37(5): 457–468.
- Leslie DL, Rosenheck R. Shifting to outpatient care? Mental health use and cost under private insurance. *The American Journal of Psychiatry* 1999; 156: 8.
- Mehta SS, Suzuki S, Glick HA, Schulman KA. Determining an episode of care using claims data. Diabetic foot ulcer. *Diabetes Care* 1999; 22(7): 1110–1115.
- Meltzer M, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: Priorities for intervention. *Emerging Infectious Diseases* 1999; 5(5): 659–671.
- Zhao S, Arguelles L, Dedhiya S, Morgan D. Healthcare utilization associated with dyspepsia in patients with arthritis. *American Journal of Managed Care* 1999; 5(10): 1285–1295.



## 1998

---

- Croghan T, Melfi C, Crown W, Chawla A. Cost-effectiveness of antidepressant medication. *The Journal of Mental Health Policy and Economics* 1998; 1: 109–117.
- Croghan T, Obenchain R, Crown W. What does treatment of depression really cost? *Health Affairs* 1998; 17(4): 198–208.
- Crown W, Obenchain R, Englehart L, Lair T, Buesching D, Croghan T. The application of sample selection models to outcomes research: The case of evaluating effects of antidepressant therapy on resource utilization. *Statistics in Medicine* 1998; 17: 1943–1958.
- Crown W, Hylan T, Meneades L. Antidepressant selection and use and healthcare expenditures: An empirical approach. *Pharmacoeconomics* 1998; 13(4): 435–448.
- Dedhiya S, Zhao S, Arguelles L. Comparison of prevalence rates of low back disorders obtained from two large national claims databases. *Value in Health* 1998; 1(1): 59–60.
- Goodman AC, Nishiura E, Hankin JR. A discrete choice model of drug abuse treatment location. *Health Services Research* 1998; 33: 125–145.
- Goodman AC, Nishiura E, Hankin JR. Short term drug abuse treatment costs and utilization: A multi-employer analysis. *Medical Care* 1998; 36: 1214–1227.
- Holzer S, Juday TR, Joelsson B, Crawley JA. Determining the cost of gastroesophageal reflux disease: A decision analytic model. *The American Journal of Managed Care* 1998; 4(10): 1450–1460.
- Hylan TR, Meneades L, Crown WH, Melfi CA, Croghan TW, Buesching DP. SSRI antidepressant drug use patterns in the naturalistic setting: A multivariate analysis. *European Psychiatry* 1998; 13(4 Suppl.): 262s–263s.
- Hylan T, Crown W, Meneades L, Heiligenstein J, Melfi C, Croghan T, Buesching D. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: A multivariate analysis. *Journal of Affective Disorders* 1998; 47: 71–79.
- Kong SX, Hatoum HT, Zhao SZ, Agrawal NM, Geis SG. Prevalence and cost of hospitalization for gastrointestinal complications related to peptic ulcers with bleeding or perforation: Comparison of two national databases. *American Journal of Managed Care* 1998; 4(3): 399–409.
- Larson MJ, Farrelly M, Hodgkin D, Miller K, Lubalin J, Witt E, McQuay L, Simpson J, Pepitone A, Manderscheid R, Keme A. Payments and use of services for mental health, alcohol, and other drug abuse disorders: Estimates from medicare, medicaid, and private health plans. SAMHSA/CMHS (Center for Mental Health Services) Mental Health, United States, 124–141, 1998.
- Lestina DC, Miller TR, Smith GS. Creating injury episodes using medical claims data. *The Journal of Trauma* 1998; 45(3): 565–569.



- Ozminkowski R, Hylan T, Melfi C, Meneades L, Crown W, Croghan T, Robinson R. Economic consequences of selected serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P450 system. *Clinical Therapeutics* 1998; 20(4): 780–796.
- Rosen AK, Houchens RL, Gibson TB, Mayer-Oakes A. Developing episodes of care for adult asthma patients: A cautionary tale. *American Journal of Medical Quality* 1998; 13: 25–35.
- Simon L, Zhao S, Arguelles L, Lefkowitz J, Dedhiya S, Fort J, Johnson K. Economic and gastrointestinal safety comparisons of etodolac, nabumetone, and oxaprozin from insurance claims data from patients with arthritis. *Clinical Therapeutics* 1998; 20(6): 1218–1235, discussion 1192–1193.
- Spiritus E, Chang R, Zhang J, Horn R, Notario G, Conway D, Palmer R, Craft J. Cost savings of clarithromycin compared with erythromycin or cefaclor in the treatment of lower respiratory tract infection: Results of a randomized, multicenter study. *The American Journal of Managed Care* 1998; 4(10 Suppl.): S562–S570.
- Zhao S, Arguelles L, Wong J, Davis M, Gersh G, Struthers B. Cost comparisons between nafarelin and leuprolide in the treatment of endometriosis. *Clinical Therapeutics* 1998; 20(3): 592–602.

## 1997 and before

.....

- Croghan T, Lair T, Englehart L, Crown W, Copley-Merriman C, Melfi C, Obenchain R, Buesching D. Effect of antidepressant therapy on health care utilization and costs in primary care. *Psychiatric Services* 1997; 48(11): 1420–1426
- Brooks J, Dor A, Wong H. Hospital-insurer bargaining: An empirical investigation of appendectomy pricing. *Journal of Health Economics* 1997; 16(4): 417–34.
- Goodman AC, Nishiura E, Humphreys RS. The cost and usage impacts of treatment initiation: A comparison of alcoholism and drug abuse treatment. *Alcoholism: Clinical and Experimental Research* 1997; 21: 931–938.
- Goodman AC, Hankin JR, Nishiura E. Drug abuse treatment costs: An interpretive essay, in Daniel M. Fox, Joel A. Egertson, and Alan I. Leshner, Eds., *Treating Drug Abusers Effectively*, Cambridge MA: Blackwell Publishers 1997: 159–186.
- Hillman A, Schwarz J, Willian M, Peskin E, Roehrborn C, Oesterling J, Mason M, Maurath C, Deverka P, Padley R. The cost effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. *Urology* 1996; 47(2): 169–78.
- Hillman BJ, Joseph CA, Mabry MR, Sunshine JH, Kennedy SD, Noether M. Frequency and costs of diagnostic imaging in office practice—A comparison of self-referring and radiologist-referring physicians. *New England Journal of Medicine* 1990; 323: 1604–1608.
- Holzer S, Englehart L, Crown W, L’Herrou T, Kennedy S. Asthma treatment costs using inhaled corticosteroids. *The American Journal of Managed Care* 1997; 3(6): 733–739.
- Hylan T, Neslusan C, Baldrige M, Meneades L, Crown W. SSRI antidepressant selection and anxiolytic and sedative-hypnotic use. *Journal of Clinical Outcomes Management* 1997; 4(4): 16–22.



THOMSON REUTERS

Lowe F, McDaniel R, Chmiel J, Hillman A. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. *Urology* 1995; 46(4): 477–83.

Stano M, Smith M. Chiropractic and medical costs of low back care. *Medical Care* 1996; 34(3): 191–204.

To contact Thomson Reuters regarding these and other authored studies, please call +1 866 301 5419 or e-mail [medstat.marketscan@thomson.com](mailto:medstat.marketscan@thomson.com).

MarketScan is a registered trademark of Thomson Reuters (Healthcare) Inc.

(280)